Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group.
And yet when you look at the trial results, overall survival was 2 months longer than those who took placebo(10.2vs8months).
Why was this even published? Coz its by a pharma company sponsored trial
Best Integrative, Alternative, Complementary Cancer Center, Manila 